Antineoplastic Agents ; therapeutic use ; Arsenicals ; therapeutic use ; Humans ; Myelodysplastic Syndromes ; drug therapy ; Oxides ; therapeutic use

Bone marrow mesenchymal stem cells (BMSCs) are a group of pluripotential non-hematopoietic somatic stem cells niched in bone marrow.With the characteristics of stable genetic traits,pluripotential in differentiation,easy to isolate from source tissue,and fast to proliferate when cultured in vitro,BMSCs are currently attracting extensive research interests,and considered to be one of the most promising candidates in corneal tissue engineering.At present,many research groups,domestic and abroad,have reported that BMSCs can not only differentiate into corneal limbal stem cells,corneal epithelial cells,and corneal endothelial cells,but also play an important role in ocular surface repair.However,the successful application of BMSCs in cornea usually depends on the correct selection of supporting materials or scaffold,such as xenogeneic corneal stroma and amniotic membrane.Other unsolved problems in BMSCs-related corneal tissue engineering include the molecular biologic mechanism underlying the directional differentiation from BMSCs to corneal cells,the standards to identify BMSCs from differentiated corneal cells,the optimal scaffold materials and the potential tumorigenicity with grafting of transformed or undifferentiated BMSCs.This paper reviewed the progresses and issues of corneal tissue engineering with BMSCs.

Cardiovascular Diseases ; Follistatin-Related Proteins ; physiology ; Humans

Aged ; Female ; Foreign Bodies ; pathology ; Humans ; Laryngeal Diseases ; Larynx ; pathology ; Vestibule, Labyrinth

Acute Disease ; Bone Marrow Neoplasms ; pathology ; Hematologic Neoplasms ; pathology ; Humans ; Immunohistochemistry ; In Situ Hybridization, Fluorescence ; Leukemia ; pathology ; Lymphoma ; pathology ; Myelodysplastic Syndromes ; pathology ; Neoplasm Invasiveness ; Plastic Embedding ; Purpura, Thrombocytopenic, Idiopathic ; pathology

American Medical Association ; Humans ; Lymphoma, Mantle-Cell ; therapy ; United States

Animals ; Betaine-Homocysteine S-Methyltransferase ; therapeutic use ; Homocysteine ; blood ; Hyperhomocysteinemia ; blood ; therapy ; Male ; Rats ; Rats, Wistar ; Recombinant Proteins ; therapeutic use

Cauda Equina ; injuries ; Decompression, Surgical ; Electric Stimulation Therapy ; Emergency Medical Services ; methods ; Fracture Fixation, Internal ; Humans ; Prognosis ; Spinal Cord Injuries ; prevention & control ; therapy ; Spinal Fractures ; surgery ; Spinal Fusion

Bone Demineralization, Pathologic ; prevention & control ; Dental Caries ; prevention & control ; therapy ; Dental Restoration, Permanent ; Education, Dental ; Gingivitis ; prevention & control ; Humans ; Orthodontics, Corrective ; Preventive Dentistry ; education

Objective To investigate the effect of reinforcing spleen and kidney method on adriamycin-induced CKD in rats and to explore its possible mechanism.Methods Totally 36 Sprague-Dawley rats were randomly divided into a Adriamycin-induced model group and a control group.The model group was further divided into five groups:the Adriamycin-induced model control group,bennazepril-treated group,and TCM treated low,moderate,and high dose groups.The level of serum creatinine,urea nitrogen,24hours urine protein and urine creatinine were measured at 14,28,42 days after establishing the model rats.And the protein expression of transforming growth factor-β1 (TGF-β1) and cyclin-dependent kinase inhibitor p21cip1 (p21)were detected by immunohistochemistry.Results The proteinuria was observed on the seventh day after injection of adriamycin in adriamycin nephropathy model group,and reached summit on the fourteenth day.Both TCM treated groups and benazepril group reduced the level of urine protein within 24 hours (P＜0.05),the reduction was most remarkable in the TCM high dose group.The expression of p21 and TGF-β1 (p21 288627.66±97021.65,TGF-β1 98405.14± 19216.89) in kidney increased in the model groups,while the TCM treated high dose group (p21 518886.35±6810.89,TGF-β1 222012.95± 50484.73) was significantly lower than the model control group (P＜ 0.05).Conclusion Reinforcing spleen and kidney method could decrease the level of urine protein within 24 hours by regulating the expression of p21 and TGF-β1,so thus to protect renal function and delay progress of kidney disease.